The impact of chronic viral hepatitis on patient discontinuation of treatment for latent TB [tuberculosis] infection due to hepatotoxicity in USPHS/TBTC study 26

Trial Profile

The impact of chronic viral hepatitis on patient discontinuation of treatment for latent TB [tuberculosis] infection due to hepatotoxicity in USPHS/TBTC study 26

Not stated
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2005

At a glance

  • Drugs Rifapentine (Primary) ; Isoniazid
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top